JAK/STAT Signaling


Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
-
C4650 GaliellalactoneSummary: inhibits IL-6-mediated JAK/STAT signal transduction -
A4683 Zipalertinib -
A4746 Afatinib2 CitationSummary: A covalent inhibitor targeting members of the ErbB family -
A4768 Tetramethylcurcumin -
A4783 Coenzyme Q0 -
A8969 Naquotinib -
A8970 Itacitinib adipate -
A8971 Ruserontinib -
A8972 Avitinib -
B8781 Deucravacitinib

